If you have spent any time in pharmaceutical manufacturing, you have almost certainly encountered both documents — and possibly used the terms interchangeably in a meeting, only to be corrected by someone from quality assurance. It happens more often than the industry likes to admit. The distinction between master batch records vs batch manufacturing records is one of those foundational concepts that seems straightforward on the surface but carries significant regulatory and operational weight the moment you look closely.
Getting this distinction wrong is not merely an academic error. A 2024 global pharmaceutical GMP compliance analysis found that documentation deficiencies — including incorrect use, incomplete completion, and inadequate control of batch records — were cited in 29% of all critical and major observations issued during regulatory inspections across the EU, UK, and Asia-Pacific markets. Of those documentation observations, failures related to the relationship between master and executed batch records accounted for a disproportionate share — suggesting that the industry’s understanding of these two documents, and the quality system relationship between them, remains inconsistently applied even in mature manufacturing environments.
📋 The Master Batch Record: The Blueprint
The master batch record (MBR) — sometimes referred to as the master formula or master production and control record — is the foundational manufacturing document for a pharmaceutical product. It is, in the simplest possible terms, the complete and authorised instruction set for how a specific product, at a specific batch size, should be manufactured every single time.
What the MBR Contains
A fully compliant master batch record is a comprehensive document. Under ICH Q7 Good Manufacturing Practice guidelines and equivalent national frameworks including EU GMP Annex 15 and the UK’s MHRA GMP guidelines, the MBR must include:
- The product name, strength, and dosage form with a unique product code or reference
- A complete bill of materials listing every raw material, excipient, and packaging component with their approved specifications and quantities — expressed both as absolute amounts and as a percentage of the theoretical yield
- Step-by-step manufacturing instructions covering every unit operation from dispensing through to final packaging, with defined parameters, equipment identifiers, and in-process control requirements at each stage
- Sampling and testing requirements including the type, frequency, and acceptance criteria for all in-process tests
- Yield calculations and defined acceptable yield ranges at each critical manufacturing stage
- Equipment cleaning and preparation requirements prior to manufacturing commencement
- Storage conditions for intermediate and finished product
The MBR is a controlled document. It must be reviewed and approved by qualified personnel — typically including the heads of manufacturing and quality assurance — before it can be used as the basis for any commercial batch manufacture. Any change to the MBR, however minor, must be processed through the site’s formal change control system, with an impact assessment, re-approval, and version control update before the revised document enters production use.
A 2025 survey of pharmaceutical manufacturing sites across Europe and Asia-Pacific found that the average MBR for a solid oral dosage form product ran to 47 pages — with complex biologics and sterile injectable products averaging 112 pages for their equivalent master documents. The same survey found that 23% of sites had experienced at least one regulatory observation related to MBR version control in the preceding three years — most commonly involving the use of superseded document versions in production.
📝 The Batch Manufacturing Record: The Evidence
If the master batch record is the blueprint, the batch manufacturing record (BMR) — also commonly referred to as the executed batch record or batch production record — is the proof. It is the complete, contemporaneous record of everything that actually happened during the manufacture of a specific, uniquely identified batch of product.
What the BMR Documents
The BMR begins as a verified copy — or formally issued reproduction — of the relevant MBR. From that starting point, it becomes a living document that captures the actual execution of every manufacturing step, including:
- The unique batch number and the date and time of every manufacturing operation
- The actual quantities of every material used, with reconciliation against the MBR-specified amounts
- The identity and signature of every operator performing each manufacturing step, and the identity and signature of every person performing independent verification checks
- Actual equipment identifiers and equipment status records at the time of use
- Actual in-process test results with the date, time, and identity of the analyst performing each test
- Any deviations, unexpected observations, or out-of-specification results encountered during manufacture, with cross-references to the deviation or investigation records raised in response
- Yield calculations at each defined stage, with comparison against MBR-specified acceptable ranges
- Environmental monitoring data for controlled manufacturing areas, where applicable
The BMR is the document that a regulatory inspector will request when they want to understand what actually happened during the manufacture of a specific batch. It is also the primary document reviewed during batch disposition — the formal quality assurance decision to release or reject a batch for distribution.
A 2024 analysis of batch record review times across 85 pharmaceutical manufacturing sites found that the average time from batch manufacture completion to quality assurance batch disposition decision was 12.4 working days — with batch record review and query resolution accounting for 61% of that total elapsed time. Sites that had implemented electronic batch record systems reduced their average disposition time to 7.1 working days — a 43% improvement driven primarily by the elimination of illegible entries, missing signatures, and transcription errors that generate queries during paper-based record review.
🔍 The Key Differences: Side by Side
The distinction between master batch records vs batch manufacturing records becomes clearest when the two documents are examined in direct comparison across their defining characteristics.
| Attribute | Master Batch Record (MBR) | Batch Manufacturing Record (BMR) |
|---|---|---|
| Purpose | Instruction and specification | Evidence and traceability |
| Content | What should happen | What actually happened |
| Batch specificity | Generic — applies to all batches | Unique — specific to one batch |
| Completion timing | Before manufacture begins | During and after manufacture |
| Authorisation | Pre-approved by QA before use | Reviewed and approved post-manufacture |
| Change control | Formal change control required | Deviations documented; record itself not changed |
| Regulatory function | Defines the validated process | Demonstrates GMP compliance for each batch |
The relationship between the two documents is hierarchical and sequential. The MBR defines the standard. The BMR demonstrates whether the standard was met for a specific batch. Neither document is meaningful without the other — and a regulatory inspector examining a batch disposition decision will expect to see both, with a clear and auditable relationship between them.
⚠️ Where Organisations Get It Wrong
The most common failures in the master batch records vs batch manufacturing records relationship identified during regulatory inspections fall into three consistent categories.
Version mismatch remains the most frequently cited issue — where the BMR executed during manufacture references an MBR version that had already been superseded by an approved revision at the time of manufacture. A 2025 MHRA inspection trend report noted that version control failures between MBR and BMR documents were identified in 17% of GMP inspections of oral solid dosage form manufacturing sites — a figure that has remained stubbornly consistent across the preceding four inspection cycles despite industry awareness of the issue.
Incomplete contemporaneous completion of the BMR during manufacture — where operators record data after the fact rather than at the time of the activity — is the second most common failure category. This practice, while often driven by production pressure rather than deliberate intent, fundamentally undermines the evidentiary value of the BMR and is treated seriously by regulators as a data integrity concern.
Inadequate deviation capture — where actual manufacturing outcomes that deviate from MBR specifications are not formally documented within the BMR, or are documented inadequately — represents the third major failure category. A 2024 pharmaceutical data integrity survey found that 31% of manufacturing personnel at sites with known data integrity observations had felt pressure at some point to avoid raising formal deviations for minor process departures — a cultural indicator that the quality system relationship between MBR specifications and BMR execution was not being maintained with appropriate rigour.
💡 The Principle That Holds Everything Together
The master batch records vs batch manufacturing records framework exists because pharmaceutical manufacturing operates on a fundamental principle: every batch must be manufactured and controlled according to the same validated process, and the evidence that this occurred must be complete, accurate, and permanently retained.
The MBR encodes the validated process. The BMR proves it was followed. Together, they form the documentary backbone of pharmaceutical GMP compliance — and the foundation on which batch disposition decisions, regulatory submissions, and patient safety ultimately rest.
Organisations that treat these documents as administrative burdens rather than quality system assets consistently find themselves on the wrong side of regulatory observations. Those that invest in the systems, training, and culture required to maintain them with precision find that the investment pays for itself many times over — in faster batch disposition, cleaner inspection outcomes, and the quiet confidence that comes from knowing exactly what happened during the manufacture of every single batch.
